Injectable Contraceptives Market - By Type (Progesterone-only Injectables {Depot Medroxyprogesterone Acetate}), Age Group (15-24 Years, 25-34 Years), Duration of Action (Short-acting Injectable Contraceptives), End-user, Global Forecast, 2023-2032
Published Date: July - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationInjectable Contraceptives Market - By Type (Progesterone-only Injectables {Depot Medroxyprogesterone Acetate}), Age Group (15-24 Years, 25-34 Years), Duration of Action (Short-acting Injectable Contraceptives), End-user, Global Forecast, 2023-2032
Injectable Contraceptives Market Size
Injectable Contraceptives Market size was valued to be USD 339.5 million in 2022 and is predicted to experience a sustainable growth of CAGR 3.5% from 2023 to 2032. Some of the major factors contributing to the growth of global market are growing awareness about family planning that is leading to an increase in awareness about benefits of injectable. Furthermore, the efforts undertaken by government and other organisations to enhance the availability of injectable contraceptives are contributing to the market expansion.
Injectable contraceptives are a type of birth control method that involves the administration of hormones through an injection to prevent pregnancy. These hormones typically include progestin, a synthetic form of the hormone progesterone. Injectable contraceptives are mainly available in two forms, depot medroxyprogesterone acetate (DMPA) and norethisterone enanthate (NET-EN).
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Injectable Contraceptives Market Size in 2022 | USD 339.5 Million |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 3.5% |
| 2032 Value Projection | USD 477.3 Million |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 208 |
| Tables, Charts & Figures | 309 |
| Segments covered | Type, Age Group, Duration of Action, End-user, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
COVID-19 Impact
The COVID-19 pandemic has shaken the world of birth control, especially injectable contraceptives. With family planning clinics shut down or limited, women have had fewer options to access these crucial methods. For example, in 2020, over 12 million women missed out on vital family planning services, including contraceptive injections. This led to an estimated 1.4 million unplanned pregnancies. To make matters worse, the pandemic messed with the supply chain for injectable contraceptives. Manufacturers struggled to keep up with demand, and distributors had difficulty getting the products where they needed to go. This disruption led to shortages and made it even harder for women to get the contraceptive care they need.
Injectable Contraceptives Market Driving Factors
The government and other organizations are making it easier for people to get their hands on injectable birth control, and that's a big reason why the market for these products is growing. For example, the Bill & Melinda Gates Foundation, Children's Investment Fund Foundation (CIFF), Pfizer, and Becton, Dickinson & Company (BD) teamed up in 2014 to make injectable birth control more available to millions of women in poor and middle-income countries. Since then, they've expanded their partnership and plan to distribute over 320 million doses of Pfizer's injectable contraceptive, Sayana Press, by 2030. The injections will be given using BD's Uniject auto-disable prefillable injection system. These kinds of initiatives are helping the entire injectable birth control market to grow.
Injectable Contraceptives Market Restraining Factors
The aftereffects associated with the use of injectable contraceptives are expected to restrain the growth of the market. For instance, according to report by world health organisation (WHO), the side effects associated with the use injectable contraceptives are, irregular menstrual bleeding patterns and amenorrhea (the absence of menstrual bleeding). Additionally, other than menstrual disruption, some other side effects were also observed such as, weight gain, heavier menstrual bleeding, headaches, dizziness, breast tenderness, body aches, nervousness, fatigue, and acne. Such side effects are somehow making women less interested towards the use if injectable contraceptives, thereby hampering market progress.
Injectable Contraceptives Market Analysis
Based on type, the injectable contraceptives market is segmented into progesterone-only injectables and combined injectable contraceptives. The progesterone-only injectables segment is further bifurcated into depot medroxyprogesterone acetate and norethisterone enanthate. In 2022, the progesterone-only injectables segment accounted for the largest business share of 68.8% in the market and is expected to grow at a CAGR of 3.3% in the forecast period. This growth can be attributed to the advantages incorporated such as, high level of efficacy and reliability in preventing unintended pregnancies.
Additionally, the progesterone-only injectables are suitable for a broader range of individuals, including those who may have contraindications to estrogen-containing contraceptives due to medical conditions or lifestyle factors. Moreover, the convenience of fewer injections, typically administered every three months, is another advantage, appealing to people preferring less frequent interventions, that has led to the growth of this segment.
Breaking down the market for injectable contraceptives, we can group them based on age15-24 years, 25-34 years, 35-44 years, and those over 44. In 2022, the youngest group, aged 15-24, took the lead. And they're predicted to keep growing at a solid pace of 3.2% over the next few years. Why the surge? Well, these young folks are juggling school, work, and hanging out with friends. So, they like the convenience of a shot that lasts for months. It fits right into their busy lives. Plus, injectable contraceptives are super effective at preventing unplanned pregnancies. That's a big deal for women who aren't quite ready to have kids yet. And because they're so private and discreet, women in this age group can take control of their reproductive health without broadcasting it to the world. That's why this segment is thriving and boosting the overall market.
Based on duration of action, the injectable contraceptives market is classified into short-acting injectable contraceptives and long-acting injectable contraceptives. In 2022, the short-acting injectable contraceptives segment accounted for the largest market revenue of USD 207.1 million and is expected to grow at a CAGR of 3.4% in the forecast period. This expansion can be attributed to factors such as convenient of administration, resonating with individuals seeking birth control that offers reliability without committing to a longer-term method.
Additionally, the short-acting injectables are well-suited for people who value minimal disruption to their routine or privacy, as they can receive injections discreetly. The manageable time frame between doses helps ensure consistent usage, making them an attractive option for those who might not want to commit to a daily routine, such factors have directly added to the growth of the segment.
Based on end-user, the injectable contraceptives market is classified into hospital, gynaecology clinics, and other end-users. In 2022, the hospital segment accounted for the largest market revenue of USD 159.7 million and is expected to grow at a CAGR of 3.1% in the forecast period. The growth of this segment can be attributed to factors such as reliability and controlled administration of injectable contraception. By getting it administered in the hospital, the involvement of medical personnel ensures accurate dosing, reducing the risk of user error and enhancing contraceptive effectiveness.
Additionally, the use of injectable contraceptives in hospitals allows for seamless integration with other reproductive health services, offering a comprehensive approach to patient care. That is directly enhancing more patients to opt for hospitals and leading to growth of this segment.
Based on the region, the injectable contraceptives market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2022, North America accounted for a revenue of USD 137.3 million, and it is expected to reach USD 186.9 million by 2032. This expansion can be attributed to factors such as, the region's well-established healthcare systems facilitate widespread access to a variety of contraceptive options, including injectables. Furthermore, the emphasis on reproductive health education and family planning initiatives contributes to a high level of awareness among individuals, enabling them to make informed contraceptive choices.
Also, the region's trained medical professionals ensure accurate administration and monitoring of injectable contraceptives, enhancing their reliability leading to growth of market in the North America.
Injectable Contraceptives Market Share
The prominent players in injectable contraceptives market are
- Pfizer Inc.
- Amphastar Pharmaeceutical Inc.
- Zhejiang xianju Pharmaceutical co., ltd.
- Eugia pharma
- Mylan labs ltd.
- Bayer Plc
- Teva Pharms USA
- PT Tunggal
- Incepta Pharmaceuticals
- Baxter International Inc.
These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches to maintain a competitive edge in the industry.
Injectable Contraceptives Industry News
- In August 2023, Pfizer and Becton, Dickinson & Company (BD) expanded their nearly decade-long collaboration with the bill and Melinda gates foundation, to help enable greater access to injectable contraceptives for millions of women in low- and lower-middle income countries. The expanded collaboration is expected to deliver more than 320 million doses of Pfizer’s injectable contraceptive, Sayana Press (medroxyprogesterone acetate)1 administered by BD Uniject Auto-Disable Prefillable Injection System, through 2030 and is also expected to benefit the whole market.
- In October 2018, Mylan N.V. launched medroxyprogesterone acetate injectable suspension USP, 150mg/mL single dose vial, a generic version of the brand, Pfizer’s Depo- Provera in the U.S. Mylan is offering the injectable suspension to its institutional customers after an Abbreviated New Drug Duration of action (ANDA) for the product was approved by the U.S. Food and Drug Administration (FDA). That has led to an increase in revenue growth for both Mylan and the global market.
The injectable contraceptives market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments
Click here to Buy Section of this Report
By Type
- Progesterone-only injectables
- Depot medroxyprogesterone acetate
- Norethisterone enanthate
- Combined injectable contraceptives
By Age Group
- 15–24 years
- 25–34 years
- 35–44 years
- Above 44 years
By Duration of Action
- Short-acting injectable contraceptives
- Long-acting injectable contraceptives
By End-User
- Hospital
- Gynecology clinics
- Other end-users
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of Middle East & Africa
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy